0001567619-21-012329.txt : 20210617 0001567619-21-012329.hdr.sgml : 20210617 20210617163214 ACCESSION NUMBER: 0001567619-21-012329 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210615 FILED AS OF DATE: 20210617 DATE AS OF CHANGE: 20210617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jacobs Jeffrey W CENTRAL INDEX KEY: 0001611193 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36485 FILM NUMBER: 211025162 MAIL ADDRESS: STREET 1: C/O ARDELYX, INC. STREET 2: 34175 ARDENWOOD BLVD, SUITE 100 CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARDELYX, INC. CENTRAL INDEX KEY: 0001437402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 510-745-7047 MAIL ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: NTERYX INC DATE OF NAME CHANGE: 20080611 4 1 doc1.xml FORM 4 X0306 4 2021-06-15 0 0001437402 ARDELYX, INC. ARDX 0001611193 Jacobs Jeffrey W C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, SUITE 200 FREMONT CA 94555 0 1 0 0 Chief Scientific Officer Common Stock 2021-06-15 4 M 0 7500 0.54 A 131551 D Common Stock 2021-06-15 4 S 0 7500 7.2878 D 124051 D Stock Option (Right to Buy) 0.54 2021-06-15 4 M 0 7500 0.00 D 2021-08-11 Common Stock 7500 10000 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 10, 2021. This transaction was executed in multiple trades in prices ranging from $7.242 to $7.41, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The option, which was granted on August 11, 2011 and has an expiration date of August 11, 2021, is fully vested and exercisable. /s/ Elizabeth Grammer, Attorney-in-Fact for Jeffrey W. Jacobs 2021-06-17